Arrowstreet Capital
LGND icon

Arrowstreet Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Arrowstreet Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,564
Closed -$2.91M – 2034
2026
Q1 		$2.91M Sell
14,564
-5,472
-27% -$1.08M ﹤0.01% 1310
2025
Q4 		$3.79M Buy
+20,036
New +$3.85M ﹤0.01% 1219
2021
Q1 		– Sell
-272,346
Closed -$16.9M – 2393
2020
Q4 		$16.9M Sell
272,346
-94,196
-26% -$5.37M 0.02% 650
2020
Q3 		$21.8M Buy
366,542
+111,721
+44% +$7.62M 0.03% 520
2020
Q2 		$17.8M Buy
254,821
+211,732
+491% +$13.4M 0.03% 548
2020
Q1 		$1.96M Buy
+43,089
New +$2.44M 0.01% 1071
2013
Q4 		– Sell
-20,063
Closed -$542K – 1232
2013
Q3 		$542K Buy
+20,063
New +$564K ﹤0.01% 783

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's LGND Position: Q2 2026 in Review

Arrowstreet Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 14,564 shares — an estimated $2.91M sold.

Arrowstreet Capital first reported a position in LGND in Q3 2013 and held it in 7 quarters. The position peaked at $21.8M in Q3 2020. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Arrowstreet Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 14,564 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.91M.
  • Arrowstreet Capital first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Arrowstreet Capital's Ligand Pharmaceuticals position peaked at $21.8M in Q3 2020.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.